

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 1

Suggested Formula Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g)	FIN	F 006 977v2
---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Hyaluronic Acid	TBD					
Niacinamide (Nicotinamide), USP	2.500	g				
Ethoxy Diglycol	3.0	mL				
Medisca VersaPro TM Cream Base	TBD					
Medisca LiquiGel Complex™	As required		(-)			
Sodium Hydroxide 10% Solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

<u>Ingredient-Specific Information</u>	5 2
Hygroscopic (protect from moi	sture whenever possible): Ethoxy Diglycol
Suggested Preparatory Guidelines	
Non-Sterile Preparati	ion Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error and pH testing considerations during preparation, it is suggested to measure an additional 10 to 12% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 2

Suggested Formula	Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g)	FIN	F 006 977v2
----------------------	---	-----	-------------

SUGGESTED PREPARATION (for 50 g)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Hyaluronic Acid	TBD				
Niacinamide (Nicotinamide), USP	2.500	g			
Ethoxy Diglycol §	3.0	mL	©		
Medisca VersaPro TM Cream Base	TBD				
Medisca LiquiGel Complex™	As required		1		
Sodium Hydroxide 10% Solution	As required	5	2		

- § Weigh / measure just prior to use.
- * Takes into account increased batch size conversions and density conversions, if required.

Preparatory Instruction Ingredient quantification: 1. A. Determine the potency of Hyaluronic Acid based on the certificate of analysis: 100% **MINUS** Loss on drying (from certificate of analysis) **DIVIDED BY** 100 **EQUALS** Quantity of dried Hyaluronic Acid in decimal **MULTIPLIED BY** Assay on dried basis result (from certificate of analysis) DIVIDED BY 100 **EQUALS** i. Potency of Hyaluronic Acid, in decimal



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 3

Suggested Formula	Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g)	FIN	F 006 977v2
2. Ingre	edient quantification:		
	Determine the quantity (in g) of Hyaluronic Acid required to make a 50 g batch of Hyalur Cream:	ronic A	acid 1% Topical
C	Quantity of Hyaluronic Acid required for 50 g		0.500 g
	DIVIDED BY		
P	otency of Hyaluronic Acid, in decimal (Step 1Ai)	_	
E	QUALS		
i.	Quantity of Hyaluronic Acid needed for 50 g	_	g
N	MULTIPLIED BY		
P	Processing error adjustments (10 to 12%)	1	.10 to 1.12
E	QUALS		
ii	. Quantity of Hyaluronic Acid needed plus processing error adjustments	_	g



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 4

Suggested Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g) FIN F 006 977v2 3. **Ingredient quantification:** A. Determine the actual quantity of VersaPro Cream Base to weigh for the required batch size (50 g): Total Weight of the batch 50 g **MINUS** The amount of other ingredient except Hyaluronic Acid 5.464 g **MINUS** The weight of Hyaluronic Acid (Step 2Ai) **EQUALS** i. Quantity of VersaPro Cream Base needed for 50 g **MULTIPLIED BY** Processing error adjustments (10 to 12%) 1.10 to 1.12 **EQUALS** ii. Weight of VersaPro Cream Base required plus processing error adjustments g 4. **Powder-liquid preparation:** A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend: -Hyaluronic Acid (amount determined in Step 2Aii) -Niacinamide (Nicotinamide)

B. Levigate the fine homogeneous powder (Step 4A) with the Ethoxy Diglycol.

End result: Homogeneous paste-like dispersion.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 5

Suggested Formula

Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g)

FIN

F 006 977v2

5. **Medium integration:**

A. Incrementally add the homogeneous paste-like dispersion (Step 4B) to the VersaPro Cream Base (amount determined in Step 3Aii).

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous cream-like dispersion.

6. Viscosity adjustment

A. If the final result is too liquid or not thick enough, incrementally add the LiquiGel ComplexTM, about 0.5 mL at a time, to the homogeneous cream-like dispersion (Step 5A) and thoroughly mix for 2 minutes. Repeat the procedure until the desired viscosity is attained.

<u>Note</u>: The amount of LiquiGel ComplexTM could be within the range of 1% to 6%.

If the final result is gritty, pass it through the ointment mill until it becomes smooth and uniform.

7. **pH** testing:

- A. Draw an appropriate amount of the mixture (Step 6A).
- B. Test the pH of the sample. It should lie between 5.6 and 6.5.
- C. If the pH < 5.6, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 5.6 to 6.5 is obtained.

IMPORTANT: Do not allow the pH to rise above 6.5.

8. **Product transfer**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 6

Suggested Formula	Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g)	FIN	F 006 977v2
----------------------	---	-----	-------------

SUGGESTED PRESENTATION

GGESTED PKI		MIATION				
Estimated Beyond-Use Date		30 days, as per USP.	Packa Requirem		Tightly closed ointment tube/jar with topical applicator.	
	1	Use as directed. Do not exceed dose.	d prescribed	5	Keep in a dry place.	
	2	Keep out of reach of children.		6	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	
Auxiliary Labels	3	For external use only.		7	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	
		May impair mental and/or phys Use care when operating a car or		8	Cap tightly after use.	
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary					
Patient Instructions		ntact your pharmacist in the event			ns. irectly dependent on the quantity of product applied.	



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/29/2017; Page 7

Suggested Formula	Hyaluronic Acid 1%, Niacinamide 5% Topical Cream (Emulsion, 50 g)	FIN	F 006 977v2

REFERENCES

1.	Ointments, Creams, and Pastes. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 265.
2.	Diethylene Glycol Monoethyl Ether. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 7 th Edition. American Pharmaceutical Association; 2012: 256.
3.	Hyaluronic Acid. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition.</i> London, England: The Pharmaceutical Press; 2009: 2320.
4.	Nicotinamide. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition.</i> London, England: The Pharmaceutical Press; 2009: 1957.
5.	Hyaluronic Acid (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #4796.
6.	Nicotinamide (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #6608.
7.	Niacinamide (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34.</i> Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 5052.
8.	Niacinamide. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional</i> , 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2183.
9.	USP <795>. <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 617.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.